SS-31 (elamipretide): the mitochondrial peptide that actually went to trial — and mostly missed

Most frontier peptides fail the same way: interesting in mice, untested in humans. SS-31 — elamipretide, also called MTP-131 — is the interesting exception. It’s been carried into large, well-designed human trials by a real biotech program. That makes it more credible than the average vial-and-forum peptide, and it also means we can do something we usually can’t: look at what happened when it was actually tested. The answer is humbling.

The mechanism is clean and specific. SS-31 concentrates in the inner mitochondrial membrane and binds cardiolipin, a phospholipid that organizes the machinery of energy production. By stabilizing that structure, the theory goes, it should restore mitochondrial efficiency in tissues where energy metabolism has broken down — which is why it was tested in conditions defined by mitochondrial dysfunction. It’s a genuinely reasonable hypothesis, well beyond hand-waving.

What the evidence actually shows

Then the trials read out, and the pattern is “mostly missed, with flickers.”

• Primary mitochondrial myopathy (MMPOWER-3, Phase 3). This was the big one: a randomized, placebo-controlled trial of 218 patients. Elamipretide did not meet its co-primary endpoints — the 6-minute walk test and a fatigue score. A later subgroup analysis found a signal in patients with specific nuclear-DNA (nDNA) defects, which is hypothesis-generating, not proof. Overall, in the population it was designed for, the drug did not beat placebo.
• Dry age-related macular degeneration (ReCLAIM-2, Phase 2). Elamipretide missed its primary visual and anatomic endpoints. A secondary measure — slowed thinning of the retina’s ellipsoid zone — was encouraging enough that the developer pursued it as an endpoint in later development, but the trial as designed was negative.
• Heart failure. Earlier work in heart failure with preserved and reduced ejection fraction likewise failed to produce the convincing efficacy that would drive approval.

This is why the grade here is C rather than D: the evidence is real human RCT evidence, not rodent extrapolation. But “real trials” and “positive trials” are different things, and honesty means saying that most of these primary endpoints were not met. The most accurate one-sentence summary is that elamipretide has been seriously tested and has mostly not delivered on its primary outcomes — with a few subgroup signals that responsible researchers are still chasing.

The adult context: not approved, and not what the vendors imply

As of 2026, elamipretide is not FDA-approved for any indication. It remains an investigational drug. That single fact should reframe everything the supplement market says about “SS-31.”

Because here’s the disconnect: the peptide-vendor world sells “SS-31” as an anti-aging and performance compound — more energy, better recovery, healthier mitochondria in healthy people. But that’s not what was tested. The trials studied sick tissue in defined diseases, and even there the drug mostly didn’t clear the bar. There is no human evidence that SS-31 enhances performance, longevity, or energy in a healthy adult. Selling it that way runs ahead of the science by a wide margin.

And the sourcing problem is the usual one, made sharper by the fact that this is a real experimental drug. The “SS-31” for sale is an unregulated copy of a compound still in trials — unknown purity, unknown dose accuracy, no sterility guarantees, injected by you at home. It is also broadly prohibited in tested sport.

The honest bottom line

SS-31 is the frontier peptide that earned its trials — and that’s exactly why it deserves a sober verdict rather than a hyped one. In the diseases it was built for, it mostly didn’t beat placebo, and it isn’t approved for anything. If you have a diagnosed mitochondrial disorder, the legitimate path is a specialist and possibly a clinical trial, where dosing and safety are monitored and the science is still being written. For a healthy person hoping to buy “mitochondrial optimization” from a peptide site, the trials have quietly already answered the question, and the answer is: not shown. Watch the later-stage programs. Until one succeeds and gets approved, this belongs in a clinician conversation, not your cabinet.